Pembrolizumab plus pemetrexed and platinum in nonsquamous non–small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study
MC Garassino, S Gadgeel, G Speranza… - Journal of Clinical …, 2023 - ascopubs.org
Clinical trials frequently include multiple end points that mature at different times. The initial
report, typically on the based on the primary end point, may be published when key planned …
report, typically on the based on the primary end point, may be published when key planned …
Pembrolizumab plus chemotherapy in squamous non–small-cell lung cancer: 5-year update of the phase III KEYNOTE-407 study
S Novello, DM Kowalski, A Luft, M Gümüş… - Journal of Clinical …, 2023 - ascopubs.org
Clinical trials frequently include multiple end points that mature at different times. The initial
report, typically based on the primary end point, may be published when key planned co …
report, typically based on the primary end point, may be published when key planned co …
[HTML][HTML] 24-month overall survival from KEYNOTE-021 cohort G: Pemetrexed and carboplatin with or without Pembrolizumab as first-line therapy for advanced …
H Borghaei, CJ Langer, S Gadgeel… - Journal of Thoracic …, 2019 - Elsevier
Abstract Introduction Cohort G of KEYNOTE-021 (NCT02039674) evaluated the efficacy and
safety of pembrolizumab plus pemetrexed-carboplatin (PC) versus PC alone as first-line …
safety of pembrolizumab plus pemetrexed-carboplatin (PC) versus PC alone as first-line …
Pembrolizumab plus pemetrexed‐platinum for metastatic nonsquamous non–small‐cell lung cancer: KEYNOTE‐189 Japan Study
H Horinouchi, N Nogami, H Saka, M Nishio… - Cancer …, 2021 - Wiley Online Library
Pembrolizumab plus pemetrexed‐platinum significantly improved overall survival (OS) and
progression‐free survival (PFS) with manageable safety compared with placebo plus …
progression‐free survival (PFS) with manageable safety compared with placebo plus …
Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non–small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study
SM Gadgeel, JP Stevenson, CJ Langer, L Gandhi… - Lung Cancer, 2018 - Elsevier
Objectives Platinum-based chemotherapy for advanced non–small-cell lung cancer
(NSCLC) has modest benefit overall, but has the potential to amplify immune responses. In …
(NSCLC) has modest benefit overall, but has the potential to amplify immune responses. In …
[HTML][HTML] Pembrolizumab plus chemotherapy for squamous non–small-cell lung cancer
L Paz-Ares, A Luft, D Vicente, A Tafreshi… - … England Journal of …, 2018 - Mass Medical Soc
Background Standard first-line therapy for metastatic, squamous non–small-cell lung cancer
(NSCLC) is platinum-based chemotherapy or pembrolizumab (for patients with programmed …
(NSCLC) is platinum-based chemotherapy or pembrolizumab (for patients with programmed …
[HTML][HTML] Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final …
D Rodríguez-Abreu, SF Powell, MJ Hochmair… - Annals of …, 2021 - Elsevier
Background In the phase III KEYNOTE-189 study (NCT02578680), pembrolizumab plus
pemetrexed and platinum-based chemotherapy (pemetrexed–platinum) significantly …
pemetrexed and platinum-based chemotherapy (pemetrexed–platinum) significantly …
Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non–small-cell …
S Gadgeel, D Rodríguez-Abreu, G Speranza… - Journal of clinical …, 2020 - ascopubs.org
PURPOSE In KEYNOTE-189, first-line pembrolizumab plus pemetrexed-platinum
significantly improved overall survival (OS) and progression-free survival (PFS) compared …
significantly improved overall survival (OS) and progression-free survival (PFS) compared …
Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
L Gandhi, D Rodríguez-Abreu, S Gadgeel… - New England journal …, 2018 - Mass Medical Soc
Background First-line therapy for advanced non–small-cell lung cancer (NSCLC) that lacks
targetable mutations is platinum-based chemotherapy. Among patients with a tumor …
targetable mutations is platinum-based chemotherapy. Among patients with a tumor …
Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non …
MC Garassino, S Gadgeel, E Esteban, E Felip… - The Lancet …, 2020 - thelancet.com
Background Pembrolizumab plus pemetrexed–platinum led to superior overall survival and
progression-free survival, and a higher proportion of patients with a confirmed complete or …
progression-free survival, and a higher proportion of patients with a confirmed complete or …